REGENXBIO Inc. (NASDAQ:RGNX) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 1,116,071 shares, a decrease of 24.0% from the August 31st total of 1,468,875 shares. Currently, 4.1% of the company’s shares are sold short. Based on an average daily trading volume, of 321,217 shares, the days-to-cover ratio is currently 3.5 days.

Shares of REGENXBIO (NASDAQ RGNX) opened at 33.15 on Friday. The stock’s market capitalization is $1.02 billion. REGENXBIO has a 52-week low of $15.24 and a 52-week high of $33.95. The stock has a 50 day moving average of $29.89 and a 200-day moving average of $29.89.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. The business had revenue of $6.56 million during the quarter. On average, equities research analysts predict that REGENXBIO will post ($2.94) EPS for the current fiscal year.

RGNX has been the subject of a number of analyst reports. BidaskClub raised shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Saturday, August 12th. Chardan Capital upped their price objective on shares of REGENXBIO from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Bank of America Corporation upped their price objective on shares of REGENXBIO from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, September 21st. Finally, Evercore ISI initiated coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $36.20.

In other REGENXBIO news, Director Donald J. Hayden, Jr. sold 40,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $28.70, for a total transaction of $1,148,000.00. Following the completion of the sale, the director now directly owns 20,000 shares of the company’s stock, valued at $574,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 27th. The shares were sold at an average price of $32.45, for a total transaction of $649,000.00. Following the sale, the director now directly owns 20,000 shares of the company’s stock, valued at $649,000. The disclosure for this sale can be found here. Insiders have sold 184,640 shares of company stock valued at $4,865,890 over the last ninety days. Insiders own 17.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of RGNX. Legal & General Group Plc grew its position in shares of REGENXBIO by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 2,011 shares during the period. Ardsley Advisory Partners acquired a new position in shares of REGENXBIO in the 2nd quarter valued at approximately $197,000. Oxford Asset Management acquired a new position in shares of REGENXBIO in the 1st quarter valued at approximately $206,000. American International Group Inc. grew its position in shares of REGENXBIO by 7.1% in the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock valued at $241,000 after purchasing an additional 822 shares during the period. Finally, Voya Investment Management LLC acquired a new position in shares of REGENXBIO in the 2nd quarter valued at approximately $249,000. Institutional investors and hedge funds own 73.26% of the company’s stock.

WARNING: “REGENXBIO Inc. (RGNX) Short Interest Update” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/regenxbio-inc-rgnx-short-interest-update/1611364.html.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.